No Data
No Data
Zevra (ZVRA) Rises on Update on Niemann-Pick Disease Type C Drug
The FDA will hold the meeting with GeMDAC on Aug 2 to review the NDA.
Zevra Therapeutics (ZVRA) Surges 21.9%: Is This an Indication of Further Gains?
FDA Convenes Expert Panel Meeting For Zevra Therapeutics' Arimoclomol, Analyst Optimistic About Approval Despite Small Patient Base
The FDA will convene a meeting with the recently formed Genetic Metabolic Diseases Advisory Committee (GeMDAC) on August 2 to review the marketing application for Zevra Therapeutics Inc.'s (NASDAQ:
H.C. Wainwright Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Maintains Target Price $15
H.C. Wainwright analyst Oren Livnat maintains $Zevra Therapeutics(ZVRA.US)$ with a buy rating, and maintains the target price at $15.According to TipRanks data, the analyst has a success rate of 40.2%
Express News | HC Wainwright & Co. Reiterates Buy on Zevra Therapeutics, Maintains $15 Price Target
Zevra Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/09/2024 190.14% HC Wainwright & Co. $15 → $15 Reiterates Buy → Buy 04/03/2024 190.14% HC Wainwright &
No Data